 VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a generation of novel medicines for anxiety, depression, and other central nervous system disorders, primarily through nasal sprays. VistaGen has three therapeutics in their pipeline across 14 indications. VistaGens lead therapeutic, PH94B, is an FDA-fast-tracked neuroactive nasal spray aiming to initiate recruitment for a Phase 3 in 2Q2021. 